Looks like there`s been an error while trying to load this page.
Our team has been notified but please contact us using the email support widget if the problem persists.
| Metrics | Range | Conclusion |
|---|---|---|
| Selected LTM EBIT Multiple | 17.7x - 19.6x | 18.7x |
| Selected Fwd EBIT Multiple | 10.6x - 11.7x | 11.1x |
| Fair Value | €170.10 - €194.33 | €182.22 |
| Upside | -26.0% - -15.5% | -20.8% |
| Benchmarks | Ticker | Full Ticker |
| Quest Diagnostics Incorporated | DGX | NYSE:DGX |
| Cryo-Cell International, Inc. | CCEL | NYSEAM:CCEL |
| Guardant Health, Inc. | GH | NasdaqGS:GH |
| OPKO Health, Inc. | OPK | NasdaqGS:OPK |
| Precipio, Inc. | PRPO | NasdaqCM:PRPO |
| Labcorp Holdings Inc. | N6B | DB:N6B |
| - | - | - |
| Select LTM EBIT Multiple | |||||||
| Benchmark Companies | |||||||
| DGX | CCEL | GH | OPK | PRPO | N6B | ||
| NYSE:DGX | NYSEAM:CCEL | NasdaqGS:GH | NasdaqGS:OPK | NasdaqCM:PRPO | DB:N6B | ||
| Historical EBIT Growth | |||||||
| 5Y CAGR | 4.1% | -2.6% | NM- | NM- | NM- | -3.8% | |
| 3Y CAGR | -16.2% | 5.4% | NM- | NM- | NM- | -28.9% | |
| Latest Twelve Months | 13.5% | 1631.0% | -7.7% | 0.1% | 53.2% | 9.8% | |
| Historical EBIT Profit Margin | |||||||
| 5 Year Average Margin | 17.7% | 11.3% | -92.2% | -17.2% | -91.9% | 15.1% | |
| Prior Fiscal Year | 14.5% | -0.8% | -85.3% | -18.3% | -50.1% | 9.2% | |
| Latest Fiscal Year | 14.3% | 11.9% | -60.0% | -38.4% | -22.7% | 8.7% | |
| Latest Twelve Months | 14.4% | 11.9% | -55.6% | -40.3% | -12.3% | 9.2% | |
| Current Trading Multiples | |||||||
| EV / LTM Revenue | 2.53x | 1.46x | 9.79x | 1.80x | 1.16x | 2.11x | |
| EV / LTM EBITDA | 12.9x | 9.7x | -19.4x | -6.9x | -19.8x | 15.6x | |
| EV / LTM EBIT | 17.6x | 12.2x | -17.6x | -4.5x | -9.4x | 23.1x | |
| Low | Mid | High | |||||
| Benchmark EV / LTM EBIT | -17.6x | -4.5x | 17.6x | ||||
| Historical EV / LTM EBIT | 8.6x | 12.5x | 22.6x | ||||
| Selected EV / LTM EBIT | 17.7x | 18.7x | 19.6x | ||||
| (x) LTM EBIT | 1,234 | 1,234 | 1,234 | ||||
| (=) Implied Enterprise Value | 21,868 | 23,019 | 24,170 | ||||
| (-) Non-shareholder Claims * | (5,812) | (5,812) | (5,812) | ||||
| (=) Equity Value | 16,056 | 17,207 | 18,358 | ||||
| (/) Shares Outstanding | 83.1 | 83.1 | 83.1 | ||||
| Implied Value Range | 193.21 | 207.06 | 220.91 | ||||
| FX Rate: USD/EUR | 1.2 | 1.2 | 1.2 | Market Price | |||
| Implied Value Range (Trading Cur) | 166.06 | 177.97 | 189.87 | 230.00 | |||
| Upside / (Downside) | -27.8% | -22.6% | -17.4% | ||||
| Equity Waterfall | |||||||
| Benchmark Companies | |||||||
| (in millions) | DGX | CCEL | GH | OPK | PRPO | N6B | |
| Enterprise Value | 26,475 | 47 | 8,099 | 1,195 | 25 | 28,050 | |
| (+) Cash & Short Term Investments | 319 | 4 | 523 | 267 | 1 | 647 | |
| (+) Investments & Other | 153 | 0 | 16 | 13 | 0 | 160 | |
| (-) Debt | (6,384) | (16) | (1,334) | (396) | (3) | (6,603) | |
| (-) Other Liabilities | (118) | 0 | 0 | 0 | 0 | (17) | |
| (-) Preferred Stock | 0 | 0 | 0 | 0 | 0 | 0 | |
| (-) Other | 0 | 0 | 0 | 0 | 0 | 0 | |
| Value of Common Equity | 20,445 | 35 | 7,304 | 1,080 | 23 | 22,237 | |
| (/) Shares Outstanding | 111.8 | 8.1 | 124.7 | 793.8 | 1.6 | 83.1 | |
| Implied Stock Price | 182.83 | 4.37 | 58.57 | 1.36 | 14.30 | 267.60 | |
| FX Conversion Rate to Trading Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.16 | |
| Implied Stock Price (Trading Cur) | 182.83 | 4.37 | 58.57 | 1.36 | 14.30 | 230.00 | |
| Trading Currency | USD | USD | USD | USD | USD | EUR | |
| FX Rate to Reporting Currency | 1.00 | 1.00 | 1.00 | 1.00 | 1.00 | 1.16 | |